SCYX

Scynexis

4.430

+0.200+4.73%

After Hours: 4.350 -0.080 -1.81%19:31 07/02 EDT

Daily

Weekly

Monthly

Quarterly

Yearly

OPEN/PREV CLOSE4.260/4.230

TODAY RANGE4.150-4.740

VOL222.01K

MARKET CAP43.99M

52 WEEK RANGE3.680-10.48

AVG VOL (3M)65.25K

% TURNOVER2.24%

TURNOVER--

P/E (TTM)-1.1383

% RANGE12.53%

EPS(TTM)-3.8919

P/E(FORWARD)-1.0858

P/B0.8318

BVPS5.33

DIVIDEND--

P/S1.170

BETA--

DIV YIELD0.00%

FREE FLOAT MKT CAP43.18M

SHARES OUTSTANDING9.93M

NEXT EARNINGS08/11-08/17

FREE FLOAT9.75M

LOT SIZE1

EX-DATE06/01/2026

News

Press Releases

Financial Reports

Profile

TipRanks·2d ago
Analysts Offer Insights on Healthcare Companies: SCYNEXIS (SCYX) and Abivax SA Sponsored ADR (ABVX)
TipRanks·3d ago
Scynexis: Buy Rating Reiterated as Rare Disease Pipeline Advances; $32 Price Target Maintained
TipRanks·4d ago
Scynexis initiates SCY-770 study
PUBT·4d ago
SCYNEXIS starts Phase 1 trial of SCY-770 AMPK activator in ADPKD program
Benzinga·4d ago
SCYNEXIS Starts Phase 1 Trial Of SCY-770 Activator Of Two Dosing Regimens
Reuters·4d ago
SCYNEXIS - TOPLINE PHASE 1 DATA EXPECTED IN Q3 2026
Reuters·4d ago
SCYNEXIS INITIATES PHASE 1 STUDY OF SCY-770, A NOVEL AMPK ACTIVATOR FOR THE TREATMENT OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD)
TipRanks·06/26 20:39
SCYNEXIS Shareholders Approve Governance and Equity Plan Changes
PUBT·06/26 20:02
SCYNEXIS boosts authorized shares to 65,000,000 from 23,750,000
TipRanks·05/31 13:45
Upcoming Stock Splits This Week (June 1 to June 5) – Stay Invested
Reuters·05/30 07:28
NASDAQ TRADE HALT <SCYX.O> HALT NEWS PENDING AT 03:28 AM
TipRanks·05/29 23:51
Scynexis trading halted, news pending
PUBT·05/29 20:02
SCYNEXIS enacts 1-for-8 reverse stock split effective May 29
Benzinga·05/26 09:44
Stock Market Today: S&P 500, Dow Jones Futures Gain Despite US 'Defensive Strikes' On Iran—Elbit Systems, Intuitive Machines, Zscaler In Focus
Benzinga·05/26 06:13
AutoZone, Zscaler And 3 Stocks To Watch Heading Into Tuesday

Same Industry

Name/Symbol

Change%

Price

SCYX

McKesson

MCK

-0.04%

763.51

Biogen Inc

BIIB

+6.97%

216.03

Amgen Inc

AMGN

-0.22%

361.33

Shire

SHPG

0.00%

179.20

Bristol-Myers Squibb Company Celegne Contingent Value Rights

CELG-RT

0.00%

0.0900

CELG

Lilly Eli & Co

LLY

+7.13%

Therapeuticsmd Inc

TXMD

-2.31%

2.110

Johnson & Johnson

JNJ

+3.99%

254.66

Abbvie Inc

ABBV

+4.20%

253.35

Zoetis Inc

ZTS

-2.22%

76.09

Gilead Sciences Inc

GILD

+3.26%

127.88

Novo-Nordisk A/S

NVO

+0.90%

48.07

Bristol-Myers Squibb Co

BMY

+3.85%

57.52

Alexion Pharms

ALXN

+1.70%

182.50

PFE

Sanofi FR

SNY

+2.75%

42.95

Sanofi FR

GCVRZ

0.00%

0.8711

Novartis

NVS

+0.19%

155.41

Dr Reddys Labs

RDY

-3.38%

14.86

No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.